One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication, Dr Jebb said
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
Its designed to offer a gentler start while pairing medication with Nooms coaching and habit-building tools
Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the receptor every GLP-1 compound binds), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (tied to glucose handling and GLP-1 secretion) describe the metabolic terrain a clinician prescribes into
Urology 75 , 14521458 (2010)
BjorkstenBAit-KhaledNInnes AsherMClaytonTORobertsonC
